Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice

W. Feleszko, Adam Giermasz, J. Golab, R. Zagozdzon, W. Lasek, M. Jakobisiak

Research output: Contribution to journalArticle

Abstract

Lovastatin, a drug used in the treatment of hypercholesterolemia was reported previously to exert synergistic antitumor activity in mice, when used together with tumor necrosis factor-α (TNF-α). As interferon-γ (IFN-γ) was also demonstrated previously to synergistically potentiate antitumor activity of TNF-α, we decided to use lovastin together with TNF-α and IFN-γ in treatment of melanoma MmB 16. Statistically significant inhibition of tumor growth was observed in mice treated with combination of all these agents in comparison to each of the remaining experimental groups. The results of this study extend the previous findings of synergistic efficacy of lovastatin and TNF-α and suggest that the effectiveness of local treatment may be augmented by the use of two or more synergistically acting agents in murine tumor models.

Original languageEnglish (US)
Pages (from-to)25-28
Number of pages4
JournalCentral-European Journal of Immunology
Volume21
Issue number1
StatePublished - 1996
Externally publishedYes

Fingerprint

Lovastatin
Interferons
Melanoma
Tumor Necrosis Factor-alpha
Hypercholesterolemia
Neoplasms
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology

Cite this

Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice. / Feleszko, W.; Giermasz, Adam; Golab, J.; Zagozdzon, R.; Lasek, W.; Jakobisiak, M.

In: Central-European Journal of Immunology, Vol. 21, No. 1, 1996, p. 25-28.

Research output: Contribution to journalArticle

@article{de75f45349ea4ef6af4abb57f00ad513,
title = "Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice",
abstract = "Lovastatin, a drug used in the treatment of hypercholesterolemia was reported previously to exert synergistic antitumor activity in mice, when used together with tumor necrosis factor-α (TNF-α). As interferon-γ (IFN-γ) was also demonstrated previously to synergistically potentiate antitumor activity of TNF-α, we decided to use lovastin together with TNF-α and IFN-γ in treatment of melanoma MmB 16. Statistically significant inhibition of tumor growth was observed in mice treated with combination of all these agents in comparison to each of the remaining experimental groups. The results of this study extend the previous findings of synergistic efficacy of lovastatin and TNF-α and suggest that the effectiveness of local treatment may be augmented by the use of two or more synergistically acting agents in murine tumor models.",
author = "W. Feleszko and Adam Giermasz and J. Golab and R. Zagozdzon and W. Lasek and M. Jakobisiak",
year = "1996",
language = "English (US)",
volume = "21",
pages = "25--28",
journal = "Central-European Journal of Immunology",
issn = "1426-3912",
publisher = "Termedia Publishing House Ltd.",
number = "1",

}

TY - JOUR

T1 - Augmented antitumor effect of tumor necrosis factor-α used together with interferon-γ and lovastatin against MmB16 melanoma in mice

AU - Feleszko, W.

AU - Giermasz, Adam

AU - Golab, J.

AU - Zagozdzon, R.

AU - Lasek, W.

AU - Jakobisiak, M.

PY - 1996

Y1 - 1996

N2 - Lovastatin, a drug used in the treatment of hypercholesterolemia was reported previously to exert synergistic antitumor activity in mice, when used together with tumor necrosis factor-α (TNF-α). As interferon-γ (IFN-γ) was also demonstrated previously to synergistically potentiate antitumor activity of TNF-α, we decided to use lovastin together with TNF-α and IFN-γ in treatment of melanoma MmB 16. Statistically significant inhibition of tumor growth was observed in mice treated with combination of all these agents in comparison to each of the remaining experimental groups. The results of this study extend the previous findings of synergistic efficacy of lovastatin and TNF-α and suggest that the effectiveness of local treatment may be augmented by the use of two or more synergistically acting agents in murine tumor models.

AB - Lovastatin, a drug used in the treatment of hypercholesterolemia was reported previously to exert synergistic antitumor activity in mice, when used together with tumor necrosis factor-α (TNF-α). As interferon-γ (IFN-γ) was also demonstrated previously to synergistically potentiate antitumor activity of TNF-α, we decided to use lovastin together with TNF-α and IFN-γ in treatment of melanoma MmB 16. Statistically significant inhibition of tumor growth was observed in mice treated with combination of all these agents in comparison to each of the remaining experimental groups. The results of this study extend the previous findings of synergistic efficacy of lovastatin and TNF-α and suggest that the effectiveness of local treatment may be augmented by the use of two or more synergistically acting agents in murine tumor models.

UR - http://www.scopus.com/inward/record.url?scp=0029930703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029930703&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 25

EP - 28

JO - Central-European Journal of Immunology

JF - Central-European Journal of Immunology

SN - 1426-3912

IS - 1

ER -